QHRD107 capsule，Venclexta and Azacitidine
Phase 2Small molecule
QHRD107 capsule，Venclexta and Azacitidine is one of 32 small molecule programs targeting Acute Myeloid Leukemia. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
31
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
804 competitors in Acute Myeloid Leukemia
#DrugCompanyPhaseTrials
1Neupogen
EEastern Cooperative Oncology Group
Phase 3
Cerubidine
HHikma Pharmaceuticals LLC
Phase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Novantrone
EMD SeronoPhase 3
Epogen
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Phase 3
Alkeran
AApotex Inc.
Phase 3
Decadron
AAspen Global Incorporated
Phase 3
Dalalone
CCSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Phase 3
Campath
GGenzyme, a Sanofi Company
Phase 3
Salvage Chemotherapy
Daiichi SankyoPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details